Use Of A Digital Application To Implement Healthy Habits And Deal With Symptoms Associated With Breast Cancer Treatment: Fatigue, Sexual Dysfunction, Insomnia And Hot Flushes

Overview

About this study

The population of breast cancer (BC) survivors has reached 3.6 million and continues to grow, concomitant with a projected shortage of oncology providers. BC survivors often feel lost in the year following definitive treatment, and they are not only at risk for recurrence but also risk for persistent treatment-related symptoms. Novel ways to care for a booming population of survivors are needed. This study explores the usability of an interactive care plan (ICP), a digital tool to actively engage and guide breast cancer survivors in their post-treatment, longitudinal care. The ICP provides digital support to assesses common side effects of therapy, as well as signs and symptoms associated with recurrence. It furthermore provides individualized, ‘just in time’ education materials to promote self-management for those reporting difficult to control symptoms, as well as escalations to contact their care team for signs or symptoms concerning for recurrence. The ICP also includes regular reminders to be physically active given its association with improved clinical outcomes, as well as an annual reminder to obtain breast imaging surveillance (when appropriate).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Patients will be eligible for participation if they have a biopsy-proven, stage I – III breast cancer and are within 6 months of completion of locoregional breast cancer treatment and (as indicated) neoadjuvant and/or adjuvant chemotherapy. Ongoing treatment with adjuvant endocrine, bisphosphonate, and single-agent, HER2-directed therapy during the study period is allowed.  Potential participants will be excluded if they are unwilling to return to Mayo Clinic for protocol-specified visits, unable to provide consent, speak or read English, or participate in mild activity or if they are pregnant.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Daniela Stan, M.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Daniela Stan

5072660034

stan.daniela@mayo.edu

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions